Cyclohexenone Compound Inhibits Ras Processing in Leukemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for leukemia lack effective compounds that target the underlying mechanisms of the disease, particularly the Ras signaling pathway, leading to limited therapeutic options and potential side effects.
Innovation Solution
A pharmaceutical composition comprising a therapeutically effective amount of a cyclohexenone compound, specifically a farnesylated quinone derivative isolated from Antrodia camphorata, which inhibits farnesyltransferase activity, thereby blocking Ras processing and triggering antitumor activity through multiple signaling pathways, including ERK1/2 and AMPK.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current leukemia treatments are used, then therapeutic options are limited, but side effects and complications increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of cyclohexenone compounds through various substituents (R1-R7 groups) to optimize therapeutic efficacy against leukemia while reducing side effects. The structural variations allow tuning of the compound's interaction with farnesyltransferase and downstream signaling pathways.
Solution Approach 2:
The cyclohexenone compound acts as an intermediary agent that blocks farnesyltransferase activity, thereby preventing Ras processing and downstream oncogenic signaling. This intermediary mechanism provides a targeted approach to leukemia treatment, offering new therapeutic options with potentially reduced side effects compared to conventional treatments.
2Reliability
If farnesyltransferase activity is inhibited, then Ras processing is blocked, but therapeutic efficacy against leukemia is enhanced
Solution Approach 1:
The patent extracts and targets the specific farnesyltransferase enzyme in the Ras signaling pathway as a therapeutic intervention point. By isolating this specific enzymatic step for inhibition, the treatment addresses the root cause of leukemia pathogenesis with a targeted mechanism, enhancing therapeutic efficacy while providing a clear molecular target.
Solution Approach 2:
The cyclohexenone compound performs preliminary action by blocking farnesyltransferase activity before Ras can be processed and activated. This pre-emptive inhibition prevents the downstream activation of oncogenic signaling pathways, effectively stopping the disease process at an early molecular stage.
3Object-generated harmful factors
If cyclohexenone compounds are used, then Ras processing is inhibited, but apoptosis and autophagy are induced
Solution Approach 1:
The patent employs inversion by inducing apoptosis and autophagy - normally protective or neutral cellular processes - to eliminate cancer cells. By hijacking these physiological pathways through farnesyltransferase inhibition, the treatment converts normal cellular mechanisms into therapeutic weapons against leukemia, enhancing cancer cell death while utilizing the body's own cellular processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclohexenone compound effectively inhibits Ras processing and induces apoptosis and autophagy in cancer cells, demonstrating potential as a therapeutic agent for treating or reducing the risk of leukemia with reduced side effects and complications.
Implementation Method 1
inhibits farnesyltransferase activity, thereby blocking Ras processing
Data Source
Figure 1
Figure 2A~2C
Figure 3A~3C
AI summary
The present invention provides methods and compositions for treating leukemia by cyclohexenone compounds. Leukemia (leukaemia) is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature while blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader group of diseases affecting the blood, bone marrow, and lymphoid system, which are all known as hematological neoplasms.